Apionex Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
- Revenue Growth 3.77%
- Profit Growth 55.75%
- Ebitda 54.82%
- Net Worth 116.41%
- Total Assets 10.49%
About Apionex Pharma
Apionex Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 October 2018 (Six years and four months 6 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 Cr.
Nirav Shah, Pratik Agnihotri, Chintal Laliwala, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U33209MH2018PTC315329
-
Company No.
315329
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Oct 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Apionex Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pratik Agnihotri
|
Director | 05-Oct-2018 | Current |
|
Nirav Shah
|
Director | 05-Oct-2018 | Current |
| Chintal Laliwala | Additional Director | 11-Dec-2024 | Current |
| Nikita Shah | Director Appointed In Casual Vacancy | 09-Dec-2024 | Current |
Financial Performance of Apionex Pharma.
Apionex Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.77% increase. The company also saw a substantial improvement in profitability, with a 55.75% increase in profit. The company's net worth Soared by an impressive increase of 116.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apionex Pharma?
In 2023, Apionex Pharma had a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jan 2022 | Hdfc Bank Limited | ₹1.00 Cr | Open |
How Many Employees Work at Apionex Pharma?
Unlock and access historical data on people associated with Apionex Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apionex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apionex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
